Drug Profile
IkT 001Pro
Alternative Names: IkI 001; IkI-001Pro; IkT-001; IKT-001Pro PML; IKT-001Pro PVAN; Imatinib prodrugLatest Information Update: 08 Mar 2024
Price :
$50
*
At a glance
- Originator Inhibikase Therapeutics
- Class Amines; Antineoplastics; Antivirals; Benzamides; Piperazines; Pyridines; Pyrimidines; Small molecules
- Mechanism of Action Bcr-abl tyrosine kinase inhibitors; Platelet-derived growth factor receptor antagonists; Signal transduction pathway inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Chronic myeloid leukaemia
- Discontinued Human polyomavirus infections; Progressive multifocal leukoencephalopathy
Most Recent Events
- 01 Mar 2024 Inhibhikase Therapeutics plans a meeting with the FDA to discuss cardiopulmonary applications of IkT 001Pro in April 2024
- 07 Feb 2024 Inhibikase Therapeutics completes pre-NDA meeting with the US FDA to discuss IkT-001Pro's pathway to approval for blood cancers
- 04 Dec 2023 USFDA plans a pre-New Drug Application (pre-NDA) meeting to be held in January 2024